Response to Lavin et al (2025)'s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. - James ML; Pink AE; Woolf RT; Batty P; Mahil S; Smith CH; Whittaker S; Langan SM (The Journal of investigative dermatology, 2025)